Pharmacologic and Liability Considerations of Therapeutic Interchange with Low-Molecular-Weight Heparins

2003 ◽  
Vol 38 (7) ◽  
pp. 652-658 ◽  
Author(s):  
Carl Gainor ◽  
Gordon J Vanscoy ◽  
Cynthia S Niccolai ◽  
Thomas L Rihn

Therapeutic interchange (TI), a formulary management process, is used by health care systems to help contain medication costs. A scientifically defensible and pharmacoeconomically beneficial TI program adheres to rigorous criteria enforced by an institution's Pharmacy and Therapeutics Committee. In situations where adherence to essential criteria is not mandated, TI may not produce the intended clinical and economic outcomes, and in practice may have legal implications. Appropriate application of TI has been described within the position statements of certain health care organizations and associations. Due to the high cost and frequent use of low-molecular-weight heparins (LMWHs), health care institutions have identified this pharmacologic class as a potential target for TI. Currently, the application of the TI process to LMWHs is questionable. This paper reviews the TI process and explores its controversial role in the formulary management of LMWHs.

2000 ◽  
Vol 57 (19) ◽  
pp. 1800-1802
Author(s):  
Kristen A. Bollinger ◽  
Lee C. Vermeulen ◽  
Stephanie N. Davis ◽  
Eric A. Geurkink

2013 ◽  
Vol 3 (4) ◽  
pp. 180-184
Author(s):  
Amy M. VandenBerg

Automatic therapeutic substitution protocols have become common practice in health care systems in the last ten to fifteen years. These protocols can help formulary management, simplify pharmacy inventory, and reduce costs. To date, psychotropics continue to be absent from the most common automatic substitution policies. This article will describe the rationale for select psychotropic substitutions.


2000 ◽  
Vol 17 (1) ◽  
pp. 1-12 ◽  
Author(s):  
William E. Wade ◽  
Bradley C. Martin ◽  
Jeffrey A. Kotzan ◽  
William J. Spruill ◽  
Marie A. Chisoholm ◽  
...  

2003 ◽  
Vol 38 (3) ◽  
pp. 202-211 ◽  
Author(s):  
Gilles L. Fraser ◽  
Joe P. Mckenna

This feature examines the impact of pharmacologic interventions on the treatment of the critically ill patient — an area of health care that has become increasingly complex. It will review recent advances (including evolving and controversial data) in drug therapy for adult ICU patients and assess these new modalities in terms of clinical, humanistic, and economic outcomes.


2000 ◽  
Vol 57 (4) ◽  
pp. 368-372 ◽  
Author(s):  
Kristen A. Bollinger ◽  
Lee C. Vermeulen ◽  
Stephanie N. Davis ◽  
Eric A. Geurkink

2000 ◽  
Vol 57 (19) ◽  
pp. 1800-1800 ◽  
Author(s):  
Henry I. Bussey ◽  
David W. Hawkins ◽  
James B. Groce

2004 ◽  
Vol 171 (4S) ◽  
pp. 42-43 ◽  
Author(s):  
Yair Latan ◽  
David M. Wilhelm ◽  
David A. Duchene ◽  
Margaret S. Pearle

Sign in / Sign up

Export Citation Format

Share Document